Journal Article Summary
The article reviews the interactions between newer direct-acting antiviral agents (DAAs) used to treat chronic hepatitis C and other commonly prescribed medications. This topic is significant because hepatitis C affects millions globally and can lead to serious health issues, including liver disease and cancer. Understanding how these DAAs interact with other drugs is crucial for optimizing treatment, preventing adverse effects, and ensuring effective therapy.
The authors conducted a comprehensive literature search to identify relevant studies on the pharmacokinetics and drug-drug interactions (DDIs) associated with four specific DAA regimens: sofosbuvir/velpatasvir, sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir, and elbasvir/grazoprevir. They found numerous clinically significant interactions, particularly with NS3/4A protease inhibitors, which were more likely to cause DDIs than other types of DAAs. While many interactions were predictable based on the drugs' properties, some were unexpected and could lead to severe consequences, necessitating careful management and monitoring.
The review highlights several limitations, including the reliance on studies conducted in healthy individuals, which may not accurately reflect how patients with hepatitis C metabolize these drugs. Additionally, the lack of comprehensive data on all possible interactions means that some recommendations are based on limited evidence. Patients should discuss their full medication list with healthcare providers before starting DAA therapy to avoid potential interactions and ensure safe treatment. It is essential for clinicians to assess and adjust medications as needed to minimize risks and enhance the effectiveness of hepatitis C treatment.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Hong Jenny, Wright Robert C., Partovi Nilu, Yoshida Eric M., Hussaini Trana. Review of Clinically Relevant Drug Interactions with Next Generation Hepatitis C Direct-acting Antiviral Agents. Journal of Clinical and Translational Hepatology 2020. DOI: 10.14218/JCTH.2020.00034. PMID: 33083256. PMCID: PMC7562806.
Featured Pill Pals Product
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) --- Perrigo --- Over The Counter
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) — Perrigo — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
